Marburg Virus Disease

Published Date : Oct 2023
Category : Infectious Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

"Marburg Market Insights: Tracing an Approach Ahead"

“Unlocking the Market Potential of Marburg Virus Disease for Sustainable Business Development”

Marburg virus disease is a highly contagious infection that produces hemorrhagic fever and the typical mortality rate in MVD cases is roughly 50% stated by WHO. Depending on viral strain and case care patient mortality rates ranged from 24% to 88% reported by WHO. It corresponds to the virus that causes Ebola virus disease.

However, the Ghanaian Ministry of Health reported 3 confirmed cases of Marburg Virus Disease (MVD), including 2 fatalities, between June 28 and September 16, 2022. All three of the cases were from the same family.

Marburg Virus disease (MVD) is a condition with a high case fatality rate. Because of the similarities in clinical symptoms, it is difficult to identify MVD from many other tropical febrile infections in the early stages of the disease.

The common symptoms of Marburg virus disease are high temperature, severe headache, and severe malaise. Aches and pains in the muscles are typical symptoms. On the third day, severe watery diarrhea, stomach discomfort and cramps, nausea, and vomiting occur.

Diarrhea might last up to a week. At this stage, patients have been characterized as having "ghost-like" drawn features, deep-set eyes, expressionless faces, and profound lethargy. However, death occurs most frequently between 8- and 9-days following symptom start and is commonly preceded by substantial blood loss and shock.

However, the Government of Equatorial Guinea (GREG) reported a Marburg virus disease (MVD) epidemic on February 13, 2023, the country's first outbreak of the disease. Several provinces, notably Kie-Ntem, Littoral, and Centro Sur, have recorded cases.

In addition to that, on May 15, the authorities announced the outbreak over, stating 16 confirmed cases and 12 deaths. During this epidemic, a further 23 suspected cases, all of which were fatal, were also documented.

Moreover, human infection with Marburg virus disease is caused by prolonged exposure to mines or caves where Rousettus bat populations live. Once infected, the virus spreads through human-to-human transmission by direct contact with infected people's blood, secretions, organs, or other body fluids, as well as surfaces and objects contaminated with these fluids.

Furthermore, Tanzanian government officials announced the country's first Marburg virus disease epidemic on March 21, 2023. The CDC's Tanzania national office immediately offered assistance with surveillance, epidemiology, and data administration.

On May 31, the epidemic was declared finished in Tanzania, with one probable and 8 confirmed cases, and 5 fatalities. All the incidents occurred in the country's northwest Kagera area.

People are at risk of getting Marburg virus disease if individuals come into touch with Egyptian rousette bats (Rousettus aegyptiacus, the reservoir host), or their urine or excretions, contact with a person who is suffering from Marburg virus disease and non-human primates infected with the virus.

To mitigate Marburg virus disease outbreaks, several sectors must work together to develop and deploy the required technologies and resources. To ensure willingness and prompt reaction to Marburg virus epidemics, public health authorities, pharmaceutical firms, healthcare organizations, and other stakeholders must collaborate.

The market for MVD is continuously growing market because of the high prevalence and death rate due to MVD, the absence of early diagnostic kits, lack of complete curable therapy and medicine. Also, finding the exact cause and detection of MVD is another variable that is impacting the market of MVD.

All of the listed above ways promote key players to perform concentrated research in the treatment and diagnostic field of MVD. However, such chances create various opportunities for new industry players to enter this field and grow their businesses.

DiseaseLandscape Insights allows all industry participants to select the ideal sector for them to grow and establish a great business in the treatment and diagnostic domains of MVD.

Diagnostic Analysis of Marburg Virus Disease

"The Innovative Approach of Marburg Virus Diagnostics: A Comprehensive Evaluation"

Clinically, MVD is difficult to identify from other infectious disorders such as malaria, typhoid fever, shigellosis, meningitis, and other viral hemorrhagic fevers. The below listed diagnostic techniques are used to confirm that symptoms are caused by Marburg virus infection:

Blood samples of patients are tested for the presence of antibodies of the anti-Marburg virus. Antibody-Capture Enzyme-Linked Immunosorbent Assay (ELISA), serum neutralization tests, reverse transcriptase polymerase chain reaction (RT-PCR) assay and electron microscopy assist in diagnosis of Marburg virus disease.

However, many healthcare organizations and governments are increasing testing, which is propelling the healthcare sector forward. For example, in September 2022, the U.S. FDA announced different programs and substantial efforts to conduct diagnostic tests in all feasible rural and urban locations as part of its ongoing effort to deal with existing outbreaks.

Moreover, the excellent specificity, sensitivity, and speed of amplification of PCR tests have contributed to the rise of the Marburg virus disease diagnostic industry. The other diagnostic test for Marburg virus disease has been challenged by PCR. However, PCR has long been recognized to dominate confirmatory tests due to its superior accuracy over other test kits on the market.

DiseaseLandscape Insights contributes to industry leaders with the creation of various diagnostic kits, the use of new technologies for enhancing existing diagnostic methods, and the supply of data on current market participants and their products to get a better understanding of market dynamics. DLI services assist businesses in navigating the complex requirements of the industry, being competitive, and contributing to public health through enhancing Marburg virus diagnosis.

Diagnostic Market Player


Becton Dickinson


Proteintech Europe Ltd

AuthentiKine™ ELISA kits


Boster's Picokine™ ELISA kits


Elabscience® ELISA test

Repligen Corporation

CTech FlowVPX System


Treatment Analysis of Marburg Virus Disease

“Advancements in the Treatment of Marburg Virus Disease: Shaping the Future”

Treatment for MVD includes supportive therapy, such as rehydration with oral or intravenous fluids and treatment of particular symptoms, does enhances the survival of MVD patients. Moreover, the care of severe instances is typically done by monitoring the patient's vital signs and health status stability. It is critical to keep blood pressure and oxygen levels consistent, as well as address any blood electrolyte imbalances.

However, there are currently no licensed vaccinations or antiviral therapies available for MVD. The European Medicines Agency (EMA) granted marketing authorization to Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) against EVD.

Galidesivir, an antiviral medication, operates by terminating RNA chains and decreasing viral RNA polymerase activity. Its effectiveness was demonstrated in six cynomolgus monkeys infected with MARV. As a consequence, survival rates increased along with viremia levels, and clotting times reduced. Nonetheless, the results of the human trials have not yet been published.

In the West African outbreak, Favipiravir, a broad-spectrum antiviral medication, was used to treat Ebola virus disease (EVD). In the case of MVD, positive results were obtained when IV Favipiravir was provided to six cynomolgus macaques infected with the virus, five of which survived. Furthermore, Remdesivir has been shown to be effective against both EVD and MARV in NHPs.

There are several opportunities for business entities in the MVD treatment industry. Participants in the market focus on the production of various cost-effective therapeutic goods, as well as the redevelopment of current medicines via the application of new technologies to enhance patient health while increasing business profit.

DiseaseLandscape Insights conducts extensive research on the treatment of MVD disease to keep clients one step ahead of the competition. DLI provides information about options for therapy, new drugs, and treatments, as well as goods and services. DLI also performs thorough studies on competitors in the treatment sector and creates unique treatment options for improved patient health.

The worldwide MVD market is extremely competitive and continuously growing. The market leaders listed below are redefining the domain and pushing innovations in the search for better health outcomes and their advanced product names.

Treatment Market Player


Johnson & Johnson

Zabdeno (Ad26.ZEBOV)

Johnson & Johnson

Mvabea (MVA-BN-Filo)



Fujifilm Holdings

Favipiravir (Avigan)


Market Trends

"Marburg Virus Market Trends: A Data-Driven Vision"

The market for MVD is very competitive and booming because there is no treatment available for MVD. There are no accurate and sensitive early-detecting diagnostic kits for patients. Manufacturers are focusing on launching novel drugs, vaccines, and antiviral options in the market to promote the health of patients while expanding their businesses.

However, there has been continuous research into vaccinations, diagnostics, and therapy possibilities for Marburg virus disease. There had been some progress, and experimental vaccinations were being developed. The number of instances, however, needed to be improved for large-scale clinical studies. Key players have various opportunities in therapies and vaccine production to grow their businesses across the globe and generate huge revenue.

Experiments are now being conducted to find the most feasible and safe therapies for MVD. Some are still being studied on nonhuman primates (NHPs) with doubtful efficacy, while others have progressed to full human trials.

Antivirals, phosphorodiamidate morpholino oligomers (PMOs), polyclonal and monoclonal antibodies, small-interfering RNA (siRNA), tumor necrosis factor and interleukin-1 (IL-1) antagonists, and interferons are among the potential therapies for MVD. The stakeholders should consider these options as an opportunity for them to discover and launch a novel product in the market.

Moreover, monoclonal antibodies (mAbs) are being developed, as are antivirals such as Remdesivir and Favipiravir, which have been used in clinical trials for Ebola Virus Disease (EVD) and researched for MVD or used under compassionate use/expanded access. Many industry players should enter the vaccine market of MVD to increase their economy and set the standard for other companies.

Regulatory Framework for Marburg Virus Disease

“Exploring Regulatory Approval: Determining Best Strategies for Business”

The regulatory structure that governs the MVD industry is crucial in ensuring patient safety, therapeutic efficacy, and market integrity. Regulatory organizations such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established strict requirements for the licensing of MVD-related medications, treatments, and medical devices.

Furthermore, regulatory agencies have offered standards to both healthcare practitioners and people for correct diagnosis, adequate labeling, and clear communication of possible dangers and benefits.

However, the EMA granted marketing authorization to Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) against EVD in May 2020. The Mvabea virus comprises the Vaccinia Ankara Bavarian Nordic (MVA) virus, which has been engineered to generate four proteins from the Zaire ebolavirus and three additional viruses from the same family (filoviridae). The vaccination protects against MVD, but its efficacy has yet to be demonstrated in clinical studies.

DiseaseLandscape Insights offers comprehensive recommendations and guidelines for dealing with Marburg virus disease. To protect public health, all important parties must become familiar with this framework and adhere to its principles. Organizations and market participants are able to prevent, manage, and react to flare-ups of MVD and protect the safety of affected people by exploring the DiseaseLandscape Insights services.

Competitive Analysis

“Understanding the Competitive Landscape for MVD: Making Informed Choices”

The dynamic connection between pharmaceutical firms, medical device developers, and diagnostic providers is reflected in the competitive landscape of the MVD disease market. In an effort to provide cutting-edge treatment alternatives with more efficacy and fewer side effects, major industry players are intensely focused on research and development initiatives.

Novel medicine formulations, such as vaccinations and antiviral treatments, have emerged as a result of this push, and they are now vying for market share.

Along with advancements in pharmaceuticals, diagnostic industries are also making significant contributions to the industry by creating advanced tests that facilitate accurate diagnosis and division of MVD.

In addition, alliances and cooperative efforts among pharmaceutical corporations, diagnostic businesses, and research institutes are reshaping the field by promoting information sharing, expediting development procedures, and expanding market penetration into international markets. It is anticipated that competition will be fierce and tough as the industry develops further.

Companies like GlaxoSmithKline, Johnson and Johnson, and Merck and Co. are some leading market players who are involved in the development of vaccines against the filovirus family including the Marburg virus. Innovative approaches, novel strategies and advanced technology are helping the companies to establish a continuously growing business and earn a huge revenue.


Disease Landscape Insights (DLI) provides vital services to the industry, streamlining patient recruitment, clinical trial procedures, and regulatory compliance for innovative treatments. It supports the healthcare sector's goal of creating innovative technologies that expand commercial opportunities in the portfolio of MVD treatments.

Disease Landscape Insight plans to evaluate the burden caused by MVD condition by considering numerous aspects that reveal future market trends for pharmaceutical businesses for research and development for MVD diagnostic tools and medicines.

Disease Landscape Insight propagates a range of market analyses and business insights created by very skilled and knowledgeable industry researchers. Numerous disease categories, such as infectious illness, chronic disease, genetic disease, autoimmune disease, mental health disorders, and environmental disease, are covered in our study papers.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape